Neoadjuvant Therapy
Showing 1 - 25 of >10,000
Rectal Cancer Trial (Neoadjuvant Chemoradiotherapy, Total Neoadjuvant Therapy)
Not yet recruiting
- Rectal Cancer
- Neoadjuvant Chemoradiotherapy
- Total Neoadjuvant Therapy
- (no location specified)
Oct 24, 2023
Colon Cancer, Neoadjuvant Therapy, Immunotherapy Trial in Guangzhou (Envafolimab, CAPEOX)
Recruiting
- Colon Cancer
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-Sen University Cancer Center
Aug 26, 2023
Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab
Not yet recruiting
- Colorectal Cancer
- +3 more
- Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
-
ZhengZhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023
Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant
Not yet recruiting
- Multiple Cancer
- Colorectal Cancer
- MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
- All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
- (no location specified)
Aug 20, 2023
Head and Neck Squamous-cell Carcinoma
Not yet recruiting
- Squamous Cell Carcinoma of Head and Neck
- +2 more
- (no location specified)
Nov 5, 2023
Breast Cancer Female Trial (Pyrotinib and Trastuzumab)
Not yet recruiting
- Breast Cancer Female
- Pyrotinib and Trastuzumab
- (no location specified)
Sep 11, 2023
Cadonilimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy Trial in Guangzhou (Cadonilimab Combined With Lenvatinib)
Recruiting
- Cadonilimab
- +2 more
- Cadonilimab Combined With Lenvatinib
-
Guangzhou, Other (Non U.s.), ChinaSun Yat-sen University Cancer Center
Nov 16, 2023
Neoadjuvant Therapy in Gastric and Gastroesophageal Cancer
Completed
- Patients With Locally Advanced Carcinoma of the Stomach and Oesophagogastric Junction
- CT scan
- (no location specified)
Sep 13, 2023
Colon Cancer, Neoadjuvant Therapy Trial in Hangzhou (Camrelizumab , apatinib and chemo)
Recruiting
- Colon Cancer
- Neoadjuvant Therapy
- Camrelizumab , apatinib and chemotherapy
-
Hangzhou, Zhejiang, ChinaFirst affiliated hospital, Zhejiang University
Jan 27, 2023
Head and Neck Squamous Cell Carcinoma, Magnetic Resonance Imaging, Neoadjuvant Therapy Trial in Guangzhou
Recruiting
- Head and Neck Squamous Cell Carcinoma
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital
Jul 27, 2023
Rectal Cancer Trial in Osaka (radiation, drug, procedure)
Recruiting
- Rectal Cancer
- Radiation
- +2 more
-
Osaka, Japan
- +1 more
Jul 1, 2023
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Trial (SHR-A1811,
Not yet recruiting
- HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
- SHR-A1811
- Trastuzumab Emtansine
- (no location specified)
Nov 7, 2023
Esophageal Carcinoma, Neoadjuvant Therapy Trial (Toripalimab, Anlotinib HCl, Albumin paclitaxel)
Not yet recruiting
- Esophageal Carcinoma
- Neoadjuvant Therapy
- Toripalimab
- +3 more
- (no location specified)
Aug 16, 2023
Esophageal Carcinoma, Neoadjuvant Immunotherapy Trial in Beijing (PD-1 blockade, Albumin paclitaxel, Carboplatin/Nedaplatin)
Recruiting
- Esophageal Carcinoma
- Neoadjuvant Immunotherapy
- PD-1 blockade
- +2 more
-
Beijing, Beijing, ChinaQin li
Mar 8, 2023
Esophageal Cancer Trial in Wuhan
Recruiting
- Esophageal Cancer
-
Wuhan, Hubei, ChinaRenmin hosptial of Wuhan University
Jun 7, 2023
Surgical Procedure, Unspecified Trial in Shanghai (ROBOTIC-ASSISTED ESOPHAGECTOMY)
Not yet recruiting
- Surgical Procedure, Unspecified
- ROBOTIC-ASSISTED ESOPHAGECTOMY
-
Shanghai, ChinaShanghai Chest Hospital, Shanghai Jiao Tong University
Aug 21, 2023
Resectable Hepatocellular Carcinoma Trial (Tislelizumab, Tislelizumab, Lenvatinib)
Not yet recruiting
- Resectable Hepatocellular Carcinoma
- Tislelizumab
- Tislelizumab, Lenvatinib
- (no location specified)
Mar 29, 2023
NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)
Not yet recruiting
- Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
- (no location specified)
Aug 27, 2023
MSS, Rectal Cancer Trial (Sintilimab with Interleukin-2)
Not yet recruiting
- MSS
- Rectal Cancer
- Sintilimab with Interleukin-2
- (no location specified)
Nov 1, 2023
Rectal Cancer in a Tertiary Asian Institute
Completed
- Rectal Cancer
- Oncology
- neoadjuvant long course chemoradiotherapy
- (no location specified)
Oct 31, 2022
Neoadjuvant Therapy for Head and Neck Squamous Cell Carcinoma
Recruiting
- Head and Neck Squamous Cell Carcinoma
-
Hangzhou, Zhejiang, ChinaSecond Affiliated Hospital, School of Medicine, Zhejiang Univers
Aug 22, 2023
Bevacizumab Combined With PD-1 Monoclonal Antibody in
Not yet recruiting
- Colorectal Cancer
- Bevacizumab Combined With PD-1 Monoclonal Antibody
- (no location specified)
Nov 8, 2023
Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer Trial in New Haven (Dapagliflozin 10mg)
Not yet recruiting
- Breast Cancer
- +2 more
- Dapagliflozin 10mg
-
New Haven, ConnecticutYale Cancer Center Smilow Cancer Hospital
Aug 3, 2023
Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
Recruiting
- Esophageal Squamous Cell Carcinoma
-
Shijiazhuang, Hebei, ChinaDepartment of Thoracic Surgery, Fourth Hospital of Hebei Medical
Oct 25, 2023